



Source details

Sapporo Medical Journal

Scopus coverage years: from 1961 to 1971, from 1973 to 2013, from 2016 to 2019, from 2021 to 2022

Publisher: Sapporo Ika Daigaku

ISSN: 0036-472X

Subject area: Medicine: General Medicine

Source type: Journal

CiteScore 2021

0.5



SJR 2021

0.111



SNIP 2021

0.076



[View all documents >](#)

[Set document alert](#)

[Save to source list](#)

[CiteScore](#) [CiteScore rank & trend](#) [Scopus content coverage](#)

i Improved CiteScore methodology ✕

CiteScore 2021 counts the citations received in 2018-2021 to articles, reviews, conference papers, book chapters and data papers published in 2018-2021, and divides this by the number of publications published in 2018-2021. [Learn more >](#)

CiteScore 2021 ▼

$$0.5 = \frac{13 \text{ Citations 2018 - 2021}}{28 \text{ Documents 2018 - 2021}}$$

Calculated on 05 May, 2022

CiteScoreTracker 2022 ⓘ

$$0.8 = \frac{13 \text{ Citations to date}}{17 \text{ Documents to date}}$$

Last updated on 05 January, 2023 • Updated monthly

CiteScore rank 2021 ⓘ

Category	Rank	Percentile
Medicine		
General Medicine	#635/826	23rd


[View CiteScore methodology >](#) [CiteScore FAQ >](#) [Add CiteScore to your site](#)



Sapporo Medical Journal

COUNTRY

Japan

 Universities and research institutions in Japan

SUBJECT AREA AND CATEGORY

Medicine
Medicine (miscellaneous)

PUBLISHER

Cancer Research Institute, Sapporo
Medical University

H-INDEX

3

PUBLICATION TYPE

Journals

ISSN


0036472X

COVERAGE

1961-1971, 1973-2013, 2016-2019,
2021

SCOPE

Information not localized


 Join the conversation about this journal

FIND SIMILAR JOURNALS 2

options :

<p>1 Neurochemistry International GBR 31% similarity</p>	<p>2 Journal of Neurochemistry GBR 31% similarity</p>	<p>3 Molecular Neurobiology USA 30% similarity</p>	<p>4 Biochemical and Biophysical Research Communications USA 30% similarity</p>	<p>5 Neurochemical Research USA 30% similarity</p>
--	---	--	---	--


SJR




Total Documents




Citations per document




Total Cites




External Cites per Doc




Cites per Doc




% International Collaboration




Citable documents




Non-citable documents



Cited documents



Uncited documents



Sapporo Medical Journal

← Show this widget in your own website

Q4
Medicine (miscellaneous)
best quartile

SJR 2021
0.11

powered by scimagojr.com

Just copy the code below and paste within your html code:

```
<a href="https://www.scimi
```

SCImago Graphica

Explore, visually communicate and make sense of data with our new data visualization tool.



Sapporo Medical Journal

Search for Journal..



SAPPORO MEDICAL JOURNAL EDITORS-PANEL

[Prof. Dr. Kazuhide Yamaoki](#)

E-mail: drkazuhide@maejournal.com

Editor-in-Chief

Graduated from the University of Tokyo .Adjunct Lecturer, Department of Cardiology, School of Medicine, The University of Tokyo. Former Lecturer / Outpatient Director, Third Department of Internal Medicine, University of Tokyo Hospital. Cardiology specialist certified by the Japanese Circulation Society. Japanese Society of Internal Medicine Certified Physician

[Prof. Dr. Soichiro Yasuda](#)

E-mail: drsoichiroyasuda@maejournal.com

Associate-Editor

Graduated from the University of Tokyo, completed the graduate school, doctor of medicine . Former Assistant Professor, Department of Cardiology, University of Tokyo Hospital .Former Researcher, Department of Physiology, University of Minnesota, USA. Former Researcher, Department of Physiology, University of Michigan, USA

[Dr. Yuichi Uchino](#)

E-mail: dryuichi@maejournal.com

Sub-Editor

Graduated from the University of Tokyo, completed the graduate school, doctor of medicine. Maemiya Office Samurai servant. Former Assistant Professor, Department of Cardiology, University of Tokyo Hospital. Cardiology specialist certified by the Japanese Circulation Society. Japan Internal Medicine Association Certified Internal Medicine Specialist

[Prof. Dr. Kazushige Washizaki](#)

E-mail: profdrkazushige@maejournal.com

Co-Editor

Graduated from the University of Tokyo, Doctor of Medicine. Part-time lecturer, Institute of Medical Science, University of Tokyo. Former Deputy Director of Neurology, Yokohama Rosai Hospital. Study abroad at NIH (National Institutes of Health). Certified Neurologist / Specialist in Neurolog

[Prof. Dr. Nobuyuki Shimizu](#)

E-mail: drnobuyuki@gmail.com

Co-Editor

Graduated from the University of Tokyo, Doctor of Medicine. Former Associate Professor of Gastroesophageal Surgery, University of Tokyo Hospital. Former Harvard Massachusetts General Hospital Research Fellow.

[Prof. dr. Kiyoshi Kikuchi](#)

E-mail: drkiyoshi@maejournal.com

Co-Editor

Graduated from Keio University, Doctor of Medicine. Visiting Professor, Department of Surgery, Keio University School of Medicine. Former Chief of Laboratory, Tokyo Electric Power Hospital and Deputy Director of Surgery. Former Researcher, Secretary Division, Laboratory, National Cancer Center.

Sapporo Medical Journal Compliance With



SEARCH RESULTS



PAPER ID : SMJ2409205408129 | VIEW : 21

**Title :** [CORRELATION BETWEEN INTERFERON- \$\gamma\$ EXPRESSION, CHOLESTASIS GRADING, AND BILIARY ATRESIA INCIDENCE IN NEONATAL CHOLESTASIS](#)**Author :** Bagus Setyoboedi, Ahmad Mahfur, Alphania Rahniayu, Anang Endaryanto, Sjamsul Arief,

Abstract : Background: Biliary Atresia (BA) is still a challenge because its pathogenesis remains unclear. It is suggested that interferon gamma (IFN- γ) has important role in its pathogenesis. Aims: To analyze correlation between IFN- γ expression, cholestasis grading, and biliary atresia incidence in neonatal cholestasis. Methods: It is an analytic observational study within neonatal cholestasis subjects 1-12 months age. Liver biopsies were performed on these subjects. Subjects were divided into biliary atresia and non-biliary atresia according to its histopathology. Then, cholestasis severity were analyzed in its liver specimens and divided into mild, moderate and poor groups. Immunohistochemistry were performed to all of the specimens. Spearman Rank test, Eta Contingency, and Coefficient contingency were performed as statistical tests. Results: There were 34 subjects consists of 20 biliary atresia and 14 non biliary atresia. The average IFN- γ expression in BA group was 11 ± 3.145 cells whereas in non-BA group was 5.928 ± 1.439 cells. Cholestasis severity in BA group were mild (0%), moderate (5%) and 95% had poor grade whereas in non BA group were 21.43%, 50%, and 28.57% respectively. There was significant correlation between IFN- γ expression and BA incidence ($r=0,904$; $p=0,00$). There was significant correlation between IFN- γ expression and cholestasis severity grades ($r=0,639$; $p=0,000$). There was significant correlation between cholestasis severity grades and BA incidence ($r=0,574$;

[Read More](#)

Sapporo Medical Journal

Sapporo Medical Journal Compliance With



INFORMATION

[Article Processing Charges](#)[Open Access Policy](#)[Terms and Conditions](#)[Privacy Policy](#)

GET TOUCH

[Information For Authors](#)[Editorial Board](#)[User Feedback](#)

Sapporo Medical Journal

© 2020 All Rights Reserved

[Sapporo Medical Journal](#)

CORRELATION BETWEEN INTERFERON- γ EXPRESSION, CHOLESTASIS GRADING, AND BILIARY ATRESIA INCIDENCE IN NEONATAL CHOLESTASIS



Bagus Setyoboedi¹, Ahmad Mahfur¹, Alphania Rahniayu², Anang Endaryanto¹, Sjamsul Arief¹

Department of Child Health, Faculty of Medicine University of Airlangga/Dr. Soetomo Hospital, Surabaya, Indonesia¹

Department of Pathology, Faculty of Medicine University of Airlangga/Dr. Soetomo Hospital, Surabaya, Indonesia²

Abstract— Background: Biliary Atresia (BA) is still a challenge because its pathogenesis remains unclear. It is suggested that interferon gamma (IFN- γ) has important role in its pathogenesis. **Aims:** To analyze correlation between IFN- γ expression, cholestasis grading, and biliary atresia incidence in neonatal cholestasis. **Methods:** It is an analytic observational study within neonatal cholestasis subjects 1-12 months age. Liver biopsies were performed on these subjects. Subjects were divided into biliary atresia and non-biliary atresia according to its histopathology. Then, cholestasis severity were analyzed in its liver specimens and divided into mild, moderate and poor groups. Immunohistochemistry were performed to all of the specimens. Spearman Rank test, Eta Contingency, and Coefficient contingency were performed as statistical tests. **Results:** There were 34 subjects consists of 20 biliary atresia and 14 non biliary atresia. The average IFN- γ expression in BA group was 11 ± 3.145 cells whereas in non-BA group was 5.928 ± 1.439 cells. Cholestasis severity in BA group were mild (0%), moderate (5%) and 95% had poor grade whereas in non BA group were 21.43%, 50%, and 28.57% respectively. There was significant correlation between IFN- γ expression and BA incidence ($r=0,904$; $p=0,00$). There was significant correlation between IFN- γ expression and cholestasis severity grades ($r=0,639$; $p=0,000$). There was significant correlation between cholestasis severity grades and BA incidence ($r=0,574$; $p=0,000$). **Conclusions:** IFN- γ was expressed higher in biliary atresia. Biliary atresia had poor cholestasis grade than non-biliary atresia in cholestasis patients.

Keywords— Biliary atresia, IFN- γ , cholestasis severity grade

1. Introduction

Biliary atresia (BA) is a liver dysfunction caused by progressive intrahepatic and extra hepatic obstruction and fibrotic of biliary duct which is marked by cholestasis.[1,2] Almost 90% of this disease occurred in perinatal period, suggested its caused by inflammation process that produced fibrotic and obstruction of biliary duct lumen.[3,4] The incidence of biliary atresia approximately 5 to 20 in 100,000 birth.[1,5] Pathogenesis of biliary atresia is suggested caused by viral infection in the liver which is followed by secondary immunology process. This process leads to progressive inflammation and produces fibro-obliteration of the biliary duct lumen as final stage.[6-9]

Immunology process which is mediated by T cell in biliary duct epithelia produces progressive autoreactive inflammation.[9-10] Interferon gamma (IFN- γ) is a cytokine which is produced by Th1 has main role in producing biliary atresia through autoreactive inflammation.[11,12] Inflammation process which is mediated by IFN- γ runs progressively will be ended as fibrotic of biliary ducts.[11] Animal model study had shown that biliary atresia incidence closely related to high expression of IFN- γ . Expression of IFN- γ increases between day 7th to 14th after Rhesus Rotavirus injection.[13-15]

Cholestasis severity grade in histopathology examination revealed obliteration grades of biliary duct.[16] Cholestasis manifestation will be better by inactivation of IFN- γ in biliary atresia animal model.[11,17] This study aims to analyze correlation between IFN- expression, cholestasis severity grades, and biliary atresia incidence in neonatal cholestasis.

2. Method

This study was an analytic observational within cholestasis patients 1-12 months as subjects. Liver biopsies were performed to all of the subjects. Then, subjects were divided into biliary atresia (BA) and non-biliary atresia (non-BA) according to its histopathology examination. Cholestasis severity were graded according to histopathology examination to all liver specimens. There were mild, moderate and poor grade. Interferon- γ expression were examined by immunohistology examination. Then, data were analyzed by using Spearman Rank test, Contingency Eta test, and Contingency Coefficient.

3. Result

There were 34 subjects, comprise of 20 biliary atresia and 14 non biliary atresia. Characteristics of these subjects were showed in table 1.

Table 1. Characteristics of subjects

Variable	Biliary atresia (n= 20)	Non biliary atresia (n= 14)	P
Percentage			
Sex			0.051
Male	6 (30%)	9 (64.29%)	
Female	14 (70%)	5 (35.71%)	
Hepatomegaly	20 (100%)	13 (92.86%)	0.232
Splenomegaly	16 (80%)	12 (85.71%)	0.672
Nutritional status			0.457
Normal	14 (70%)	8 (57.14%)	
Wasted	3 (15%)	3 (21.43%)	
Poor	3 (15%)	3 (21.43%)	
Median (interquartile)			
Age (months)	8 (1.75)	5.5 (2.25)	0.186
Duration of sickness (months)	7 (2)	5.5 (2.125)	0.341
Weight (kg)	6.1 (0.96)	4.55 (1.04)	0.007*
Height (cm)	63.5 (4.63)	56 (4.25)	0.005*
Direct bilirubin (mg/dl)	11.09 (2.29)	9.63 (2.94)	0.237
Total bilirubin (mg/dl)	14.49 (5.60)	11.32 (4.47)	0.054
SGOT (mg/dl)	264 (76.88)	204 (63)	0.142
SGPT (mg/dl)	185 (100.88)	151 (50)	0.421

The average of IFN- γ expression in biliary atresia group was 11 ± 3.145 cells whereas in non-biliary atresia

group was 5.928 ± 1.439 cells. There was significant correlation ($r = -0.467$; $p = 0.038$) between IFN- γ expression and age in BA group (Figure 1).




Figure 1. Correlation between age and IFN- γ expression in CD4 lymphocyte

Correlation between IFN- γ expression, cholestasis severity grade, and biliary atresia incidence were described in table 2. Cholestasis severity grades in BA group were mild (0%), moderate (5%), and poor (95%), whereas in non-BA group were 21.43%, 50%, and 28.75%, respectively. There was significant correlation between IFN- γ expression and biliary atresia incidence ($r = 0.904$; $p = 0.00$). There was significant correlation between IFN- γ expression and cholestasis severity grade ($r = 0.639$; $p = 0.000$), and also between cholestasis severity grade and biliary atresia incidence ($r = 0.574$; $p = 0.000$).

Table 2. Correlation between IFN- γ expression, cholestasis severity grade, and biliary atresia incidence

Variable	IFN- γ	Cholestasis severity grade	Biliary atresia incidence
IFN- γ expression			
r	1.000	0.639*	0.904**
p	0.000	0.000	0.000
Cholestasis severity grade			
r		1.000	0.574***
p		0.000	0.00
Biliary atresia incidence			
r			1.000
p			0.000

4. Discussion

Interferon- γ is a substance which is produced by TH1, NK cells and APC as a response to viral infection. This substance has role in innate and adaptive immune response.[18] Investigation of liver biopsy specimens revealed that IFN- γ expression in BA and non-BA groups were significant difference ($p < 0.05$). Interferon - γ expression in BA group was higher than non-BA group. This result was similar to previous study that IFN- γ was expressed excessively in biliary atresia patients than other type cholestasis.[19]

Interferon- γ expression revealed decreasing trend by age in BA group (Picture 1). The highest expression of IFN- γ was at 3 months. This result appropriates to previous study in animal model which shows significant enhancement of IFN- γ in day 7 and then decrease at day 14 to normal level.[20] According to conversion reference, 7 days mice equals to 2-3 months in human.[21] This study had shown, the highest expression of IFN- γ was at 3 months old equals to 7 days in mice. Flowcytometry examination revealed there was 40 times increase of IFN- γ expression in CD4+ lymphocytes at 7th day after induction. Interferon - γ is important effector for TH1 phenotype, thus excessive expression of IFN- γ in the liver consistent to IFN- γ roles in inflammation and obstruction of biliary duct. Elimination of IFN- γ expression will decrease inflammation by decreasing lymphocytes population at triad portal then there will be repairing of icterus.[20]

Interferon-Y has roles in progressivity of biliary duct obliteration through fibrotic phase.[22,23]Cholestasis severity grades by histopathology examination describes obliteration grades of biliary ducts.[16] In this study, there was indirect correlation between IFN-Y and cholestasis severity grade through fibrotic phases.

In this study, there was significant correlation between cholestasis severity grade and biliary atresia incidence. Cholestasis severity grade describes biliary ducts obstruction. Thus, it can describe non direct correlation between cholestasis severity grade and biliary atresia incidence. There was close correlation between cholestasis grades in biliary atresia patients and lumen diameter of obliterated biliary ducts.[16] Cholestasis severity grade in zone 2 and 3 acini closely related to biliary ducts and hepatocytes damage and poor prognosis.[24,25]

5. Conclusion

Interferon- γ is highly expressed in biliary atresia patients. Highest expression is at 3 months age; thus, it is suggested that intervention avoid progressivity of biliary atresia would have better results at this age. Biliary atresia patients have poor cholestasis severity grade than non-atresia biliary patients according to its histopathology.

This study has limited samples. Ideally, liver biopsy is performed by surgical operation. However, this study had given additional evidence regarding hypothesis the role IFN- γ in pathogenesis of biliary atresia. It is suggested that this study could overcome future studies in biliary atresia management.

6. References

- [1] Hartley JL, Davenport M, Kelly DA. Biliary atresia. *The Lancet* 2009;374:1704–13.
- [2] Sokol RJ, Mack C, Narkewicz MR, Karrer FM. Pathogenesis and outcome of biliary atresia: current concepts. *J Pediatr Gastroenterol Nutr*2003;37:4–21.
- [3] Carvalho E de, Ivantes CAP, Bezerra JA. Extrahepatic biliary atresia: current concepts and future directions. *J Pediatr (Rio J)* 2007;83:105–20.
- [4] Makin E, Quaglia A, Kvist N, Petersen BL, Portmann B, Davenport M. Congenital biliary atresia: liver injury begins at birth. *J Pediatr Surg* 2009;44:630–3.
- [5] Yoon PW, Bresee JS, Olney RS, James LM, Khoury MJ. Epidemiology of biliary atresia: a population-based Study. *PEDIATRICS* 1997;99:376–82.
- [6] Lee H-C, Chang T-Y, Yeung C-Y, Chan W-T, Jiang C-B, Chen W-F, et al. Association of interferon-gamma gene polymorphisms in Taiwanese children with biliary atresia. *J Clin Immunol* 2010;30:68–73.
- [7] Muraji T, Suskind DL, Irie N. Biliary atresia: a new immunological insight into etiopathogenesis. *Expert Rev Gastroenterol Hepatol*2009;3:599–606.
- [8] Neimark E, LeLeiko NS. Early detection of biliary atresia raises questions about etiology and screening. *Pediatrics* 2011;128:e1598–9.
- [9] Fujinami RS, von Herrath MG, Christen U, Whitton JL. Molecular mimicry, bystander activation, or viral persistence: infections and autoimmune disease. *Clin Microbiol Rev* 2006;19:80–94.
- [10] Huang L, Si X-M, Feng J-X. NF- κ B related abnormal hyper-expression of iNOS and NO correlates with the inflammation procedure in biliary atresia livers. *Pediatr Surg Int* 2010;26:899–905.
- [11] Shivakumar P, Campbell KM, Sabla GE, Miethke A, Tiao G, McNeal MM, et al. Obstruction of

- extrahepatic bile ducts by lymphocytes is regulated by IFN- γ in experimental biliary atresia. *J Clin Invest* 2004;114:322–9.
- [12] Schön P, Tsuchiya K, Lenoir D, Mochizuki T, Guichard C, Takai S, et al. Identification, genomic organization, chromosomal mapping and mutation analysis of the human INV gene, the ortholog of a murine gene implicated in left-right axis development and biliary atresia. *Hum Genet* 2002;110:157–65.
- [13] Erickson N, Mohanty SK, Shivakumar P, Sabla G, Chakraborty R, Bezerra JA. Temporal-spatial activation of apoptosis and epithelial injury in murine experimental biliary atresia. *Hepatology* 2008;47:1567–77.
- [14] Mack CL, Tucker RM, Lu BR, Sokol RJ, Fontenot AP, Ueno Y, et al. Cellular and humoral autoimmunity directed at bile duct epithelia in murine biliary atresia. *Hepatology* 2006;44:1231–9.
- [15] Mack CL, Sokol RJ. Unraveling the Pathogenesis and Etiology of Biliary Atresia. *Pediatr Res* 2005;57:87R–94R.
- [16] Sharma S, Das P, DattaGupta S, Kumar L, Gupta DK. Liver and portal histopathological correlation with age and survival in extra hepatic biliary atresia. *Pediatr Surg Int* 2011;27:451–61.
- [17] Kuebler JF, Czech-Schmidt G, Leonhardt J, Ure BM, Petersen C. Type-i but not type-ii interferon receptor knockout mice are susceptible to biliary atresia. *Pediatr Res* 2006;59:790–4.
- [18] Schroder K, Hertzog PJ, Ravasi T, Hume DA. Interferon- γ : an overview of signals, mechanisms and functions. *J Leukoc Biol* 2004;75:163–89.
- [19] Vejchapipat P, Poomsawat S, Chongsrisawat V, Honsawek S, Poovorawan Y. Elevated serum IL-18 and Interferon-Gamma in medium-term survivors of biliary atresia. *Eur J Pediatr Surg* 2012;22:029–33.
- [20] Shivakumar P, Sabla G, Mohanty S, McNeal M, Ward R, Stringer K, et al. Effector role of neonatal hepatic CD8+ lymphocytes in epithelial injury and autoimmunity in experimental biliary atresia. *Gastroenterology* 2007;133:268–77.
- [21] Dutta S, Sengupta P. Men and mice: Relating their ages. *Life Sci* 2016;152:244–8.
- [22] Jian Z-H, Wang L-C, Lin C-C, Wang J-D. The correlation between plasma cytokine levels in jaundice-free children with biliary atresia. *World J Pediatr* 2015;11:352–7.
- [23] Bezerra JA. The next challenge in pediatric cholestasis: deciphering the pathogenesis of biliary atresia. *J Pediatr Gastroenterol Nutr* 2006;43:S23–9.
- [24] Cielecka-Kuszyk J, Czubkowski P, Bacewicz L, Pawlowska J, Jankowska I, Szymanska-Debinska S. Comparison of histological changes in liver biopsy specimens in patient with biliary atresia of poor and good prognosis. *Annals of Diagnostic Paediatric Pathology*. 2006;10:37–42.
- [25] Gupta L, Gupta SD, Bhatnagar V. Extrahepatic biliary atresia: Correlation of histopathology and liver function tests with surgical outcomes. *J Indian Assoc Pediatr Surg* 2012;17:147–52.



This work is licensed under a Creative Commons Attribution Non-Commercial 4.0 International License.